Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
MERUS LABS Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MPH HEALTH CARE | 19,150 | +1,86 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
17.06.2025 / 16:27 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 8,150 | 0,00 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
AMARIN | 14,200 | +2,90 % | Recordati: RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA IN EUROPE | RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
Vazkepa® supported by strong clinical data package and expected to contribute to Specialty... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,810 | -1,42 % | Krebsforschungs-Expertin verstärkt wissenschaftlichen Beirat von SELLAS Life Sciences | ||
MADRIGAL PHARMACEUTICALS | 244,10 | -3,21 % | Madrigal Pharmaceuticals-Aktie: Vergleichsanalyse auf kommender Konferenz | ||
CATALYST PHARMACEUTICALS | 18,190 | +0,44 % | Catalyst Pharma: Viel Wachstum für wenig Geld? | Die meisten Biotech-Aktien sind vor allem eins: hochspekulativ. Catalyst Pharma beweist jedoch, dass es auch anders geht - mit realen Gewinnen und nachhaltigem Wachstum Den vollständigen Artikel lesen... ► Artikel lesen | |
ANI PHARMACEUTICALS | 55,50 | +0,91 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th | ||
DOGECOIN CASH | - | - | Dogecoin Cash, Inc.: Dogecoin Cash Inc. (OTCQB: DOGP) Forms Dogecoin Treasury, Inc. to Support Development of Dogecoin-Related Tools and Infrastructure | ||
ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - June 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
TITAN PHARMACEUTICALS | 0,001 | -100,00 % | Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd. | NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today the filing by Black Titan Corporation with the U.S. Securities and... ► Artikel lesen | |
BLUM HOLDINGS | - | - | BLUM HOLDINGS, INC. - 8-K, Current Report | ||
BMP PHARMA TRADING | 5,600 | 0,00 % | PTA-News: B.M.P. Pharma Trading AG: B.M.P. steigert abermals das operative Rekordjahresergebnis aus dem Jahr 2023 im Geschäftsjahr 2024 - Erhöhte Umsatzprognose und Ergebnisprognose für das Geschäftsjahr 2024/25 bestätigt | DJ PTA-News: B.M.P. Pharma Trading AG: B.M.P. steigert abermals das operative Rekordjahresergebnis aus dem Jahr 2023 im Geschäftsjahr 2024 - Erhöhte Umsatzprognose und Ergebnisprognose für das Geschäftsjahr... ► Artikel lesen | |
THERIVA BIOLOGICS | 0,432 | -4,04 % | Theriva Biologics, Inc.: Theriva Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Canc | - Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology... ► Artikel lesen | |
KAZIA THERAPEUTICS | 6,680 | +3,09 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC) | SYDNEY, June 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics... ► Artikel lesen | |
ALLERGY THERAPEUTICS | 0,083 | -1,19 % | Allergy Therapeutics - Allergy Therapeutics presents findings at EAACI |